Table 3.

League tables showing the results of the network meta-analysis comparing the effects of all drugs including odds ratios and 95% credible intervals

IL-2
0.07 (0.00–2.65)	Rituximab
0.06 (0.00–2.21)	0.88 (0.40–1.92)	Belimumab
0.06 (0.00–2.34)	0.86 (0.30–2.42)	0.98 (0.40–2.42)	Obinutuzumab
0.05 (0.00–1.75)	0.71 (0.36–1.40)	0.82 (0.54–1.23)	0.83 (0.37–1.84)	Control
0.04 (0.00–1.97)	0.65 (0.18–2.28)	0.74 (0.23–2.31)	0.76 (0.20–2.85)	0.91 (0.31–2.62)	Anifrolumab
0.05 (0.00–1.71)	0.68 (0.30–1.52)	0.78 (0.41–1.44)	0.79 (0.31–1.97)	0.95 (0.59–1.51)	1.04 (0.32–3.37)	Abatacept
0.04 (0.00–1.67)	0.65 (0.28–1.48)	0.74 (0.39–1.40)	0.76 (0.29–1.90)	0.91 (0.56–1.47)	1.00 (0.31–3.29)	0.96 (0.49–1.87)	Ocrelizumab